Canada Pension Plan Investment Board Fate Therapeutics Inc Transaction History

Canada Pension Plan Investment Board

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$3.54 - $8.35 $469,758 - $1.11 Million	132,700 New	132,700 $974,000
Q3 2022 Nov 14, 2022	BUY	$21.04 - $36.06 $12,624 - $21,636	600 Added 9.06%	7,224 $162,000
Q2 2022 Aug 12, 2022	BUY	$17.78 - $42.39 $14,224 - $33,912	800 Added 13.74%	6,624 $164,000
Q1 2022 May 13, 2022	BUY	$29.67 - $60.28 $113,636 - $230,872	3,830 Added 192.08%	5,824 $226,000
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $81,280 - $109,313	1,699 Added 575.93%	1,994 $117,000
Q3 2021 Nov 15, 2021	BUY	$59.27 - $95.73 $17,484 - $28,240	295 New	295 $17,000
Q3 2018 Nov 09, 2018	SELL	$8.75 - $16.29 $700,000 - $1.3 Million	-80,000 Closed	0 $0
Q2 2018 Aug 07, 2018	BUY	$9.16 - $13.48 $732,800 - $1.08 Million	80,000 New	80,000 $907,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $215M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Canada Pension Plan Investment Board, based on Form 13F filings with the SEC.

Stay updated on Canada Pension Plan Investment Board with notifications on news.